Currax Drug Patent Portfolio
Currax owns 1 orange book drug protected by 24 US patents Given below is the list of Currax's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8513299 | Methods of using low-dose doxepin for the improvement of sleep | 07 Sep, 2030 | Active |
| US9532971 | Low-dose doxepin formulations and methods of making and using the same | 01 Jun, 2029 | Active |
| US9107898 | Methods of using low-dose doxepin for the improvement of sleep | 01 May, 2028 | Active |
| US10548871 | Low-dose doxepin formulations and methods of making and using the same | 11 Apr, 2028 | Active |
| US11096920 | Low-dose doxepin formulations and methods of making and using the same | 11 Apr, 2028 | Active |
| US9907780 | Low-dose doxepin formulations and methods of making and using the same | 11 Apr, 2028 | Active |
| US11234954 | Low-dose doxepin for treatment of sleep disorders in elderly patients | 18 Jan, 2028 | Active |
| US7915307 | Methods of improving the pharmacokinetics of doxepin | 24 Aug, 2027 | Active |
| US10653660 | Methods of improving the pharmacokinetics of doxepin | 20 Jul, 2027 | Active |
| US11110074 | Methods of improving the pharmacokinetics of doxepin | 20 Jul, 2027 | Active |
| US9572814 | Methods of improving the pharmacokinetics of doxepin | 20 Jul, 2027 | Active |
| US10238620 | Methods of using low-dose doxepin for the improvement of sleep | 18 May, 2027 | Active |
| US10653662 | Methods of using low-dose doxepin for the improvement of sleep | 18 May, 2027 | Active |
| US12083090 | Methods of using low-dose doxepin for the improvement of sleep | 18 May, 2027 | Active |
| US9486437 | Methods of using low-dose doxepin for the improvement of sleep | 18 May, 2027 | Active |
| US9861607 | Methods of using low-dose doxepin for the improvement of sleep | 18 May, 2027 | Active |
| US6211229 | Treatment of transient and short term insomnia | 17 Feb, 2020 | Expired |
| US5585115 | Pharmaceutical excipient having improved compressability | 09 Jan, 2015 | Expired |
| US5725884 | Pharmaceutical excipient having improved compressibility | 09 Jan, 2015 | Expired |
| US5866166 | Pharmaceutical excipient having improved compressibility | 09 Jan, 2015 | Expired |
| US5948438 | Pharmaceutical formulations having improved disintegration and/or absorptivity | 09 Jan, 2015 | Expired |
| US6103219 | Pharmaceutical excipient having improved compressibility | 09 Jan, 2015 | Expired |
| US6217909 | Pharmaceutical excipient having improved compressibility | 09 Jan, 2015 | Expired |
| US5502047 | Treatment for insomnia | 26 Mar, 2013 | Expired |
Latest Legal Activities on Currax's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Currax.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 20 Aug, 2025 | US9907780 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 16 Jul, 2025 | US11234954 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 25 Jun, 2025 | US9861607 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 09 Jan, 2025 | US8513299 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 09 Jan, 2025 | US11110074 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 09 Jan, 2025 | US11096920 |
| Patent eGrant Notification | 10 Sep, 2024 | US12083090 |
| Patent Issue Date Used in PTA Calculation | 10 Sep, 2024 | US12083090 |
| Recordation of Patent Grant Mailed | 10 Sep, 2024 | US12083090 |
| Recordation of Patent eGrant | 10 Sep, 2024 | US12083090 |
| Email Notification | 10 Sep, 2024 | US12083090 |
| Mail Patent eGrant Notification | 10 Sep, 2024 | US12083090 |
| Email Notification | 22 Aug, 2024 | US12083090 |
| Issue Notification Mailed | 21 Aug, 2024 | US12083090 |
| Dispatch to FDC | 09 Aug, 2024 | US12083090 |
Currax's Drug Patent Litigations
Currax's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 08, 2011, against patent number US8513299. The petitioner , challenged the validity of this patent, with Roberta L. Rogowski et al as the respondent. Click below to track the latest information on how companies are challenging Currax's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8513299 | August, 2011 |
Decision
(07 Dec, 2012)
| Roberta L. Rogowski et al | |
Currax's Family Patents
Currax drugs have patent protection in a total of 4 countries. It has a significant patent presence in the US with 83.1% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Currax Drug List
Given below is the complete list of Currax's drugs and the patents protecting them.
1. Silenor
Silenor is protected by 24 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8513299 | Methods of using low-dose doxepin for the improvement of sleep |
07 Sep, 2030
(4 years from now)
| Active |
| US9532971 | Low-dose doxepin formulations and methods of making and using the same |
01 Jun, 2029
(2 years from now)
| Active |
| US9107898 | Methods of using low-dose doxepin for the improvement of sleep |
01 May, 2028
(1 year, 7 months from now)
| Active |
| US10548871 | Low-dose doxepin formulations and methods of making and using the same |
11 Apr, 2028
(1 year, 7 months from now)
| Active |
| US11096920 | Low-dose doxepin formulations and methods of making and using the same |
11 Apr, 2028
(1 year, 7 months from now)
| Active |
| US9907780 | Low-dose doxepin formulations and methods of making and using the same |
11 Apr, 2028
(1 year, 7 months from now)
| Active |
| US11234954 | Low-dose doxepin for treatment of sleep disorders in elderly patients |
18 Jan, 2028
(1 year, 4 months from now)
| Active |
| US7915307 | Methods of improving the pharmacokinetics of doxepin |
24 Aug, 2027
(11 months from now)
| Active |
| US10653660 | Methods of improving the pharmacokinetics of doxepin |
20 Jul, 2027
(10 months from now)
| Active |
| US11110074 | Methods of improving the pharmacokinetics of doxepin |
20 Jul, 2027
(10 months from now)
| Active |
| US9572814 | Methods of improving the pharmacokinetics of doxepin |
20 Jul, 2027
(10 months from now)
| Active |
| US10238620 | Methods of using low-dose doxepin for the improvement of sleep |
18 May, 2027
(8 months from now)
| Active |
| US10653662 | Methods of using low-dose doxepin for the improvement of sleep |
18 May, 2027
(8 months from now)
| Active |
| US12083090 | Methods of using low-dose doxepin for the improvement of sleep |
18 May, 2027
(8 months from now)
| Active |
| US9486437 | Methods of using low-dose doxepin for the improvement of sleep |
18 May, 2027
(8 months from now)
| Active |
| US9861607 | Methods of using low-dose doxepin for the improvement of sleep |
18 May, 2027
(8 months from now)
| Active |
| US6211229 | Treatment of transient and short term insomnia |
17 Feb, 2020
(6 years ago)
| Expired |
| US5585115 | Pharmaceutical excipient having improved compressability |
09 Jan, 2015
(11 years ago)
| Expired |
| US5725884 | Pharmaceutical excipient having improved compressibility |
09 Jan, 2015
(11 years ago)
| Expired |
| US5866166 | Pharmaceutical excipient having improved compressibility |
09 Jan, 2015
(11 years ago)
| Expired |
| US5948438 | Pharmaceutical formulations having improved disintegration and/or absorptivity |
09 Jan, 2015
(11 years ago)
| Expired |
| US6103219 | Pharmaceutical excipient having improved compressibility |
09 Jan, 2015
(11 years ago)
| Expired |
| US6217909 | Pharmaceutical excipient having improved compressibility |
09 Jan, 2015
(11 years ago)
| Expired |
| US5502047 | Treatment for insomnia |
26 Mar, 2013
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Silenor's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List